Catalyzing a Movement: Sharsheret Sets the Jewish Breast Cancer Agenda
Before Sharsheret, there was no Jewish response to breast cancer. Although Jewish men and women are 10 times more likely to carry a gene mutation that triggers hereditary cancers, the disease was still taboo – an unspoken malady. Sharsheret has given a voice and face to breast cancer, rallying communities across the country, encouraging healthy living, and putting hereditary cancer on the national agenda.
And it all began with Sharsheret’s participation in the Joshua Venture Group’s second cohort in 2003. Back then, Sharsheret was just getting started and the founder Rochelle Shoretz was looking for support, financial and beyond. Through the Fellowship, Shoretz jumpstarted her managerial career, developed leadership skills, and made life-long friends who continue to be sounding boards and a support network.
Today, under Sharsheret’s dynamic Shoretz:
- Educates and supports more than 45,000 Jewish women, families, communities, and students on campus
- Has a national presence with offices in New Jersey and Florida
- Serves on the Federal Advisory Committee on Breast Cancer in Young Women
- Has a budget of $2,223,705
- Employs 16 people
“The Dual Investment Program jumpstarted Sharsheret,” says Shoretz. “I attribute much of the organization’s success to the early lessons I learned thanks to Joshua Venture Group.”